fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ondansetron hydrochloride

All products: Limited Use (codes 215, 216, 217, 218, 454, 696)

Apo-Ondansetron · DIN 02291967 · 4 mg/5 mL · oral liquid

Limited Use, Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 215, 216, 217, 218, 454, 696 required
Write on scriptone applicable Reason for Use code, 215 or 216 or 217 or 218 or 454 or 696 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 215, 216, 217, 218, 454, 696
Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Apo-Ondansetron · DIN 02291967 Manufacturer: Apotex Inc.; listing date 2009-05-20 Health Canada: Marketed since 2020-12-17 · brand APO-ONDANSETRON · ATC A04AA01 ONDANSETRON · form Solution · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 4 MG/5ML · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Ondansetron: Formulary list price $0.80 per unit (the source does not state the unit; exact figure $0.7952). What the ministry pays, not the patient.

Ministry pays: $0.7952 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02291967)

Source record
DIN 02291967: Apo-Ondansetron Raw flags: sec12=Y, sec3=Y Item: 562200025; group id 671; item number 1664; lccId 00102; manufacturer id APX Source form: O/L; strength: 4mg/5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.7952; ministry $0.7952 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02291967 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77733
Interchangeable products
Jamp Ondansetron · DIN 02490617 · $0.7952 Mint-Ondansetron Solution · DIN 02524090 · $0.7952 Zofran · DIN 02229639 · not recorded
Shortage status: active shortage (reported December 30, 2025, last updated January 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291967
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A04A, A04AA): coverage varies; not interchangeable

  • Granisetron (Kytril): limited Use 326, 454, not a benefit
  • Netupitant + palonosetron (Akynzeo): limited Use 561, 562
  • Ondansetron (Zofran): not a benefit
  • Nabilone (Cesamet): general benefit, not a benefit
  • Aprepitant (Emend Tri-Pack): limited Use 452, 453
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HCL DIHYDRATE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Adults (18-64 years of age) pms-ONDANSETRON (ondansetron tablets) is indicated for: • the prevention of nausea and vomiting associated with mildly and moderately emetogenic chemotherapy, and radiotherapy. • the maintenance of antiemesis following intravenous doses of ondansetron used for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy, including cisplatin. • the prevention of post-operative nausea and vomiting. 1.1 Pediatrics (<18 years of age) Prevention of Nausea and Vomiting Associated with Mildly and Moderately Emetogenic Chemotherapy • Pediatrics (4-12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of ondansetron in pediatric patients 4-12 years of age has been established. Therefore, Health Canada has authorized an indication for pediatric use. (see 4.2 Recommended Dose and Dosage Adjustment). • Pediatrics (<4 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for the use of pms-ONDANSETRON in children less than 4 years of age. Prevention of Nausea and Vomiting Associat… https://pdf.hres.ca/dpd_pm/00077211.PDF PM date: April 19, 2006 Source product: PMS-ONDANSETRON; DIN 02258188; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Ondansetron · DIN 02291967 Shortage status: active shortage (reported 2025-12-30, last updated 2026-01-02); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291967

Check this DIN again